Hemostatic alterations caused by ventricular assist devices for postcardiotomy heart failure.
The hemostatic alterations in two adult patients who were supported by left ventricular assist devices (LVADs) because of postcardiotomy heart failure were evaluated. In both patients, fibrinopeptide A and thrombin-antithrombin III complex increased markedly during the first several days, and thereafter decreased moderately but remained above normal over the entire procedure. Furthermore, fibrinopeptide B beta 15-42 and alpha 2 plasmin inhibitor-plasmin complex were also markedly increased over the entire course of LVAD treatment. These data show that the LVAD system strongly activates both the coagulation and the fibrinolytic system, even when thromboembolic or bleeding complications are not clinically evident. Furthermore, the decrease in physiological coagulation inhibitors, especially protein C, indicates that these factors are activated and consumed during LVAD treatment. Because protein C is important in regulating the coagulation cascade during LVAD treatment, exhaustion of this system might result in thromboembolic complications during LVAD treatment.
Tanaka
K
K
Department of Cardiovascular Surgery, Toyooka Public Hospital, Japan.
Wada
K
K
Morimoto
T
T
Shomura
S
S
Nasu
M
M
Okada
Y
Y
Yada
I
I
Yuasa
H
H
Kusagawa
M
M
D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D005260:Female; D005344:Fibrinopeptide A / Q000032:analysis; D005345:Fibrinopeptide B / Q000032:analysis; D006333:Heart Failure / Q000097:blood / Q000628:therapy*; D006353:Heart-Assist Devices; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011183:Postoperative Complications / Q000097:blood / Q000628:therapy*; D011486:Protein C / Q000032:analysis
D011486:Protein C; C046193:antithrombin III-protease complex; D005344:Fibrinopeptide A; D005345:Fibrinopeptide B; D000990:Antithrombin III; D010447:Peptide Hydrolases